NSCLC

[European Journal of Pharmacology] Investigators developed a potent inhibitor of cyclin-dependent kinase 7 (CDK7), designated YPN-005, and determined whether it showed any anticancer effects in small cell lung cancer (SCLC), cells, cisplatin or etoposide-resistant cells, or organoids derived from SCLC patients.

[Scientific Reports] Scientists screened a total of 521 tumor specimens from Chinese patients with lung cancer for anaplastic lymphoma receptor tyrosine kinase fusion by immunohistochemistry and confirmed by fluorescence in situ hybridization.

[Foundation Medicine, Inc.] Foundation Medicine, Inc. announced that it has received approval from the US FDA for FoundationOne®CDx to be used as a companion diagnostic for ALUNBRIG®, which is currently FDA-approved for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer as detected by an FDA-approved test.

[Auris Medical Holding Ltd.] Auris Medical Holding Ltd. announced the selection of mutant KRAS-driven colorectal cancer as the first therapeutic indication for its OligoPhore™ oligonucleotide delivery platform, based on outcomes from studies with OligoPhore™ enabled KRAS silencing, and a well-defined regulatory and development pathway.

[BMC Cancer] BRE-AS1 was downregulated in TNBC, while miR-21 was highly expressed in TNBC. Low expression levels of long non-coding RNA BRE-AS1 and high expression levels of miR-21 were significantly correlated with unfavorable survival outcomes.

[International Journal of Molecular Sciences] The authors assessed whether circulating tumor cells (CTCs) in peripheral blood could serve as a disease surrogate, focusing on CD44 and CD74 expression as prognostic markers for brain metastases.